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ABSTRACT
The BOG25 family proteins, BOG25 and 7a5, contain domains of the EHNetwork family of endocytosis, intracellular sorting and cell fate determination proteins
as well as a C-terminal death domain that may play an important role in apoptosis. No
other known proteins contain the same domain combinations which makes this family
unique. The normal physiological roles of the BOG25 family of proteins are currently
unknown, and this is the first study of the possible role of BOG25 and 7a5 in cancer.
Additionally, this study is the first to confirm the transcription of mRNA for 7a5, the
putative protein identified as similar to BOG25 by the Human Genome Project. Three
cDNA sequences were subcloned, sequenced and aligned with 100% identity, the
predicted coding region of 7a5 from the genomic sequence submitted by the Human
Genome Project.
The hypothesis of this study is that BOG25 and 7a5 proteins play an important
role in the cancer phenotype, and therefore, will have a substantial differential expression
between the cancer cell lines and/or between the cancer and normal cell lines. Western
blot, subcellular fractionation and Reverse Transcription-Polymerase Chain Reaction
(RT-PCR) were used to analyze three sets of cell lines: bladder, prostate and breast. The
most advanced cancerous bladder cell line, HTB 5, expressed a very high level of 7a5
protein, while the most differentiated cancer cell line, HTB 2, expressed the lowest level.
Conversely, BOG25 and 7a5 proteins in prostate cell lines showed no major difference
IX

between the cell lines. However, the breast cancer cell line, Hs578T expressed BOG25
protein at a high level compared to all of the other breast cell lines. Based on these
results, the breast cell lines were further characterized using subcellular fractionation and
RT-PCR to examine mRNA and corresponding protein levels. Subcellular fractionation
revealed BOG25 expression at approximately a 1:1 ratio of PNF to NF in all breast cell
lines including Hs578T cells while 7a5 was expressed at higher levels in the PNF than
NF in all cell lines. No major alteration in subcellular localization was observed for
either BOG25 or 7a5 in the Hs578T cell line compared to the other breast cell lines. RTPCR of triplicate total RNA samples from breast cells showed that Hs578T expressed a
very high level of BOG25 mRNA compared to all other cell lines. Corresponding triplet
lysates analyzed for BOG25 and 7a5 protein expression showed that protein levels were
comparable to the mRNA levels where all cell lines expressed BOG25 at a much lower
level than Hs578T. Only one sample showed a correctly sized 7a5 mRNA band for the
MDA cell line. All samples for the other cell lines expressed similar 7a5 mRNA levels.
Triplicate 7a5 protein data showed subtle differences among cell lines that were
comparable to the mRNA data. The unique domain combinations and the highest
expression in the most advanced cancer are persuasive reasons for BOG25 and 7a5 to be
examined further as prognostic markers in breast and bladder cancer tissues, respectively

x

CHAPTER I
INTRODUCTION

BOG25 And Consensus Sequences
BOG25 is a novel 120kD protein that was first identified, sequenced, and
characterized in human corneal fibroblasts (Dunlevy el al., 1999). This research showed
that BOG25 is encoded on human chromosome 2q37. l-q37.2 by fluorescence in situ
hybridization analysis. The official gene name for BOG25 is SH3-domain-Binding
Protein 4 (SH3BP4) (Dunlevy et a l , 1999), but will remain named BOG25 in this thesis.
Encoded within the 963 amino acid open reading frame of BOG25, is a unique
combination of consensus sequences and domains that no other known protein contains
(Figure 1). The consensus sequences include: an SH3 domain, a P-X-X-P sequence,
three N-P-F motifs, a bipartite nuclear targeting sequence, tyrosine phosphorylation
sequence (Dunlevy et al ., 1999) and a death domain. BOG25 contain domains of the EHNetwork family of endocytosis, intracellular signal transduction and cell fate
determination proteins and to the death domain family of proteins.
Src-Homology 3 (SH3) domains are involved in protein-protein interactions that
include: interacting proteins with the cytoskeleton, interacting with proteins involved in
endocytosis, including clathrin vesicle formation (Simpson et al., 1999), subcellular
localization of signaling proteins, organization of protein complexes, and binding
substrates for enzymes (Pawson, 1995; Ren et al., 1993; Cohen et al., 1995).
1
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Figure 1: Consensus sequences of BOG25. The consensus regions within BOG25
include SH3 domain, N-P-F repeats, P-X-X-P sequence, bipartite nuclear targeting
sequence, tyrosine phosphorylation sequence, and death domain. Open box represents
the 963 amino acid open reading frame, and the closed boxes are the 335-nucleotide 5’
and 1920-nucleotide 3’ untranslated regions.
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Analysis of the SH3 binding site of the protein Abl (3BP2) showed the SH3 domain
binds to the amino acid sequence P-X- X-P (where P is proline, and X is any amino acid)
within a ten-amino acid proline-rich region (Ren etal., 1993). SH3 domain analysis of
Abl and Src indicates there are numerous different SH3 domains, and there are many
different binding sites/sequences on target proteins (Ren etal., 1993). SH3 domains
differentially bind the various consensus sequences causing each SH3 domain-containing
protein to require a specific target protein (Ren et al., 1993) and hence a different cellular
response. SH3 domains and P-X-X-P binding sites are also found on many EH-Network
proteins (Santolini etal., 1999). Epsl5 and Epsl5R each contain three SH3 domains,
while short intersectin and its related protein long intersectin both contain five SH3
domains each (Santolini et al., 1999).
Proteins that contain an EH domain or the EH domain binding sequence of N-P-F
belong to the EH-network (Confalonieri and Di Fiore, 2002). The EH-network (for
Epsl 5 Homology) is important in protein-protein binding in cellular functions such as
endocytosis of the epidermal growth factor receptor (EGFR) (Confalonieri etal., 2000) ,
intracellular signal transduction (Santolini et al., 1999) and cell fate determination
(Confalonieri and Di Fiore, 2002). The EH domain is 66 amino acids in length and was
first identified in Epsl 5 (Wong et al., 1995), a substrate for the tyrosine kinase activity of
epidermal growth factor receptor (EGFR) (Fazioli et a l, 1993). The N-P-F (Asn- ProPhe) amino acid sequence has been identified as a binding site for EH (E p sl5 Homology)
domains (Mayer, 1999) and is found in EH-binding proteins (Santolini et al., 1999).
Many EH-domain containing proteins and EH-binding proteins are found in pairs such as
E p s l5 and Epsl5R, NUMB and NUMBR, intersectin 1 and 2 and EH-binding proteins
3

Epsin 1 and 2 (Santolini etal., 1999). Epsl5 plays an important role in clathrin-mediated
endocytosis. Intersectin, Epsl5 and Epsl5R and an EH binding protein, Epsin, are
regulatory and assembly proteins for clathrin coat assembly and vesicle invagination
(Santolini etal., 1999). The interrelationship of EH-Network proteins and SH3 domains
shows that endocytosis is a very complex scaffolding process.
The bipartite nuclear targeting sequence is a known sequence for targeting
proteins to the nucleus (Dingwall and Larskey, 1991). The targeting sequence consists of
two basic amino acids, any ten amino acids, followed by a cluster of five amino acids of
which three must be basic (Dingwall and Larskey, 1991). Nuclear proteins that include
transcription factors, DNA polymerases and androgen and estrogen steroid hormone
receptors all contain the bipartite nuclear targeting sequence. Nonnuclear proteins such
as Epsl5R also contains the nuclear targeting sequence, although Epsl5R has also been
reported in the nucleus (Coda etal., 1998).
Tyrosine phosphorylation sequences are sequences within proteins that are
phosphorylated by receptor tyrosine kinases (Alberts et al., 2002). Receptor tyrosine
kinases are located on the plasma membrane and include EGFR. Upon binding of an
extracellular ligand (e.g. epidermal growth factor, fibroblast growth factor or insulin),
receptor tyrosine kinases dimerize, and phosphorylate the other receptor proteins and
many other proteins that contain a tyrosine phosphorylation sequence to transduce the
signal and elicit a specific response (Alberts et al., 2002). Responses of tyrosine kinases
include cell proliferation, growth and survival (Alberts et al., 2002). The EH-domain
containing proteins Epsl5 and Epsl5R are both phosphorylated by the EGFR (Fazioli et

al., 1993; Coda etal., 1998).
4

The death domain is a protein-protein interaction domain about 80 amino acids in
length found in the C-terminus in cytosolic regions of proteins involved in the apoptotic
protease cascade (Tartaglia et al., 1993). These proteins include receptors found in the
Tumor Necrosis Factor (TNT) receptor family: TNFReceptor-1 andFas/A pol (Feinstein

et a l, 1995; Reed, 2003). Adaptor, or docking proteins, associated with the TNF receptor
family also contain death domains and include Fas-Associated Death Domain/Mediator
O f Receptor-Induced Toxicity 1 (FADD/MORT1) and TNFR1-Associated Death Domain
(TRADD) (Boldin et a l, 1995; Hsu et al., 1995). Upon FasL ligand binding, the Fas
receptor aggregates and binds FADD by the death domain on each protein (Lambert et

al., 2003). FADD activates the caspase cascade leading to apoptotic cell death.
The domain combinations within BOG25 have focused recent studies on the
determination of the subcellular localization of BOG25 using fusion proteins. The
BOG25 immune IgY antibody has been shown to recognize two specific 120 kD and 100
kD bands on a Western blot, and bands for BOG25 fusion proteins that migrated correct
to size of the 120 kD band (Khanobdee et al ., 2003 Abs). Endogenous BOG25 protein
was found to localize to membrane and nuclear fractions of human retinal pigment
epithelial, ARPE-19, and COS-7 cells (Khanobdee K et al., 2003 Abs). Subcellular
fractionation studies determined BOG25 fusion proteins localized to the plasma
membrane and nuclear periphery. Confocal microscopy also showed a localization
pattern to the plasma membrane and nuclear periphery with altered cell morphology in
many but not all cells. ARPE-19 cells over-expressing full-length BOG25 fusion
proteins in the pEGFP and c-myc-tagged pCMV-Tag3 vectors show an increase in the
percent of cells with condensed nuclei compared to non-expressing neighboring cells and
5

cells containing control vectors. Additionally, an N-terminal truncated BOG25 construct
was found to be more effective than full length constructs at inducing cell rounding and
nuclear condensation (Koppelman et al., 2003 Abs; Dunlevy 2004 Abs).

7a5
The Human Genome Project recently identified a gene on chromosome 7 p l5.3
that was homologous to BOG25 and named the putative protein 7a5. 7a5 is a 105 kD
protein that is believed to be the lower 100 kD band on the Western blot; it is exactly
15kD smaller than BOG25 and its amino acid sequence is highly homologous to BOG25,
having 60% identity and similarity. The consensus sequences and domains of the 7a5
protein are similar to those of BOG25: two N-P-F EH binding motifs, one P-X-X-P SH3
binding motif, three tyrosine phosphorylation sites and one death domain that has a 75%
identity and similarity to the death domain of BOG25 (Figure 2). The 7a5 protein is
currently completely uncharacterized as nothing is known or has been published about it.

Cancer
Cancer is the second leading cause of death in the United States. It is well known
that cancer alters normal cell physiology to form abnormal cells that promote growth and
resist apoptosis. Abnormal cells include cells that have lost their ability to repair
damaged DNA, correct replication errors, maintain chromosome integrity and/or have
accumulated multiple mutations (Alberts et al., 2002). Abnormal cells that exhibit
metaplasia and neoplastic hyperplasia will create a tumor or neoplasm (Goodman and
Kelly Snyder, 2003; Alberts etal., 2002).
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Figure 2: Consensus sequences of 7a5. The consensus regions within 7a5 include 2 N-PF sequences, a P-X-X-P sequence, 3 tyrosine phosphorylation sequences, and a death
domain. The open box represents the 816 amino acid open reading frame for 7a5.
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Cancer is the uncontrolled growth and proliferation of tumors in any organ system
(Goodman and Kelly Snyder, 2003). Malignant tumors can be classified by cell type, or
named by the tissue of origin (Goodman and Kelly Snyder, 2003). Carcinoma is a cancer
originating from epithelial cells. Adenocarcinoma is a malignant tumor originating from
the lining/epithelial cells of organs or glands. Carcinosarcoma is a malignant tumor
originating from epithelial cells and connective tissue such as bone, cartilage and fat.
Tumors assume an undifferentiated phenotype, become immune evasive and apoptosis
resistant and often rearrange the extracellular matrix to then invade the surrounding
connective tissue (Goodman and Kelly Snyder, 2003). Jacks and Weinberg (2002) have
presented that the basement membrane of epithelial cells acts as a barrier between
epithelial cells and the surrounding stroma to restrict passage from the reservoir of
molecules, such as growth factors, contained within the basement membrane. Tumor
cells can secrete different compositions of extracellular matrix to gain access to the
growth factors in order to maintain survival (Jacks and Weinberg, 2002). Once
malignant tumors have invaded surrounding tissue, most often they metastasize from the
primary tumor to specific regions of the body through blood vessels created by
angiogenesis, or through the lymph system (Goodman and Kelly Snyder, 2003).
Metastatic cells can accumulate within the lymph nodes or travel through the lymph
nodes to distant organs.
There are several ways to classify, or stage, cancer. Currently, the most powerful
prognostic factor is considered the stage of the cancer (Hillegas, 2003). The TNM
(Tumor,Nodes,Metastasis) classification system is a clinical staging based on biopsies
and diagnostic tests (American Joint Committee on Cancer, 2002). TNM stands for size
8

of tumor, spread to regional lymph nodes, and presence or absence of metastasis. Type
of and histological grade of a tumor and estrogen and progesterone receptor status, in
breast and prostate cancer respectively, are also utilized in staging (Hillegas, 2003).
Histologic grade depends on the number of nuclei and aneuploidy (Hillegas, 2003). The
higher the grade is, the more aggressive the cancer, and the poorer the prognosis.
Prognosis is the prediction of a probable course or outcome of a disease. Isolation
of molecular markers such as genes, RNA and proteins from biopsy serum, urine or
lymph fluid are used as cancer prognostic markers (Sidransky, 2002). Examining DNA
mutations is valuable in monitoring metastasis and determining prognosis, while RNA
analysis is key for expression level changes or point mutations in genes and analysis of
proteins is important for differential localization or changes in protein expression
(Sidransky, 2002). Although the stage of the cancer is considered the most powerful
prognostic factor, TNM is utilized only after a cancer has progressed undetected for
possibly years within the body, with the probability that metastasis has already occurred.
Other prognostic markers are needed to identify cancer at earlier stages, monitor disease
progression and determine response to therapy (Sidransky, 2002). For example, it is well
known that early stage breast cancer patients already have microscopic metastases at
diagnosis (Esteva and Hortobagyi, 2004). However, adjuvant systemic therapies are
potentially toxic to those patients who do not need that aggressive of a therapy. Early
prognostic makers, therefore, would be beneficial in terms of decision-making regarding
therapy.

9

Apoptosis and Cancer
Apoptosis, or programmed cell death, is morphologically characterized by
chromatin condensation, nuclear fragmentation, plasma membrane blebbing and cell
shrinkage (Alberts et al., 2002). The blebs and apoptotic cells are phagocytosed by
macrophages or neighboring parenchymal cells (Alberts et al., 2002). Necrosis, on the
other hand, is death by cell lysis causing inflammation. The cell becomes swelled, the
plasma membrane is disrupted and the cell is lysed releasing cytoplasmic contents
causing disruption to surrounding tissues, and usually a damaging inflammatory response
(Alberts e ta l ., 2002).
Two well characterized pathways of apoptosis induction include the extrinsic
pathway and the intrinsic pathway (Boatright and Salvesen, 2003; Maag e ta l, 2003).
The extrinsic pathway is initiated upon ligand binding to receptors, such as TNFR-1 and
Fas, that contain a death domain (Reed, 2000). The death domain is found in both
adaptor proteins and receptors, and is important for cell death by being utilized as a
docking protein to recruit signaling proteins to the receptor (Wallach et al., 1999). The
death domain of FADD, an adaptor protein, utilizes its death domain to bind another
FADD, and/or Fas and is required for apoptosis to occur (Boldin etal., 1995; Chinnaiyan

et al., 1995; Gomez-Angelats and Cidlowski, 2003; Reed, 2000). By its death effector
domain, FADD links the Fas receptor to procaspase-8 monomers to allow dimer
formation and activation of caspase-8 (Boatright and Salvesen, 2003). This signaling
mechanism of Fas, FADD and caspase-8 is also known as the death-inducing signal
complex (Gomez-Angelats and Cidlowski, 2003).
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The intrinsic pathway involves the unbalanced ratio of anti- and pro-apoptotic
Bcl-2 family proteins favoring the pro-apoptotic family members (Reed, 2000). Caspase8 can cleave the pro-apoptotic Bid protein in the cytoplasm where Bid then translocates
to the mitochondria to release cytochrome c (Luo et a/., 1998). A caspase activating
protein Apaf-1 located in the cytosol that hydrolyzes ATP binds the released cytochromec (Zou eta l ., 1999). This complex, known as the apoptosome, binds, orients, processes
and activates procaspase-9 (Zou et a l, 1999). The intrinsic pathway eliminates cells
damaged from ionizing radiation and mitochondrial damage (Boatright & Salvesen,
2003).
Caspases are cysteine proteases that exist as zymogens until they are cleaved into
their active state. There are both initiator and effector caspases (Salveson and Dixit,
1997). The large N-terminal prodomain of initiator caspases interacts with proteins that
initiate their activation (Reed, 2003). Initiator caspases, including caspase-8 and caspase9, then cleave off the short N-terminal prodomains of effector caspases that include
caspase-3 and caspase-7 (Boatright and Salvesen, 2003). Effector caspases then cleave
DNA repair proteins, protein kinases, cytoskeletal and nuclear matrix proteins that will
cause DNA fragmentation, cell blebbing and membrane shrinking (Reed, 2000).
Phagocytosis of the blebs and the cells can then occur by macrophages or neighboring
parenchymal cells (Alberts etal., 2002).
Cancer results in acquired resistance to apoptosis that can lead to abnormal cell
longevity, a loss of dependence on exogenous growth factors, resistance to the immune
system, protection from oxidative stress and the allowance for genetic mutation
accumulation (Reed, 2003). Still, another viewpoint maintains that cells containing
11

defects in DNA repair, chromosome segregation and apoptosis allow unstable abnormal
cell viability/survival that can ultimately lead to cancer and chemoresistance (Reed,
2003).

EH-Network and Cancer
Epidermal growth factor receptor (EGFR) requires phosphorylation of Epsl5 for
its recruitment by coated pits (Di Fiore and De Camilli, 2001; Di Fiore and Gill, 1999).
Overexpression of the EGFR substrate Epsl5 has been shown to transform NIH 3T3
fibroblast cells that then have the ability to grow in soft agar (Fazioli et al., 1993). The

EpsJ5 gene has been involved in translocations in acute lymphoblastic and myeloid
leukemias (Salcini et al., 1999). The EGFR plays an important role in neoplastic cell
proliferation, angiogenesis and metastatic spread (Dancey, 2004). The overexpression of
EGFR is the most frequently reported abnormality in non-small cell lung cancer with
very poor survival prognosis with treatment (Dancey, 2004). However, trial studies show
mixed results in the effectiveness of treating EGFR in non-small cell lung cancer
(Dancey, 2004). Cancers often mutationally change the outcome of transduction of
signaling pathways to deregulate cell growth, differentiation and apoptosis (Martin, 2003)
in order to survive. Tumors can also escape inhibition o f one signaling pathway by
activating another signaling pathway (Martin, 2003). Since the EGFR is not commonly
mutated in cancers (Dancey, 2004), utilizing other signaling pathways is a possible
method of escape from aggressive therapies.
The unique combination of consensus sequences and domain homologies that
include the SH3 domain, N-P-F EH binding sequence, and death domain, indicate that
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BOG25 and 7a5 are important in protein-protein binding that may bridge intracellular
sorting and apoptosis and therefore, may be important to the cancer phenotype.

Bladder Cancer
The histology of the bladder is comprised by the urothelium (transitional
epithelium) at the lumen, surrounded by connective tissue (lamina propria), encircled by
two layers of smooth muscle (muscularis propria), and adipose tissue (adventitia).
Invasive urothelial tumors are cancers that have spread into the muscularis propria.
Bladder cancer cell lines used in this study that were invasive are HTB1, HTB 5, and
CRL-1472 (Masters et al., 1986). The HTB 2 cell line is a papillary low-grade
transitional cell carcinoma (Masters et al., 1986). HTB1 is an invasive, high grade
transitional cell carcinoma that has spread to the adventitia (Masters et al., 1986) while
HTB 5 is an invasive, metastatic high grade transitional cell carcinoma (Masters et al,
1986), and CRL-1472 is an invasive transitional cell carcinoma (Masters et al., 1986).
Papillary urothelial carcinoma consists of finger-like projections of urothelium into the
lumen of the bladder.
The total estimated bladder cancer cases in the United States for 2004 are 60,240
and the total estimated deaths are 12,710 in 2004 (Ries et al., 2001). Bladder cancer is
the fourth cause of cancer in men, and ninety to ninety-eight percent of bladder cancers
are transitional cell carcinomas (Boissannault, 2003). Mutations in the tumor suppressor
genes, p53 or Rb are considered important in the development of bladder cancer. Current
prognostic markers utilized in bladder cancer include TP53 gene mutations,
microsatelline alterations, cytokeratin and survivin RNA, survivin protein, and DNA
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hypermethylation of certain E-cadherins and death-associated protein kinase (Sidransky,
2002 ).

Prostate Cancer
The prostate is an important male gland producing the protective and nourishing
seminal fluid for sperm. The gland is only about the size of a walnut and encompasses
the urethra just below the bladder. Prostate cancer is the second cause of cancer-related
death in men (Boissannault and Goodman, 2003). Most prostate cancers grow slowly,
many of which are undetected throughout the lifetime of a man diagnosed with prostate
cancer. Many prostate cancers are found confined within the prostate or from invasion of
the seminal vesicles and urinary bladder (Boissannault and Goodman, 2003; Wilson and
Hillegas, 2003). Binding of the androgen testosterone, that is secreted primarily by the
testes, or the more active hormone 5a-dihydrotestosterone to an androgen receptor causes
the complex to enter the nucleus and activate DNA for cell growth, survival and an
elevated level of prostate specific antigen (Feldman and Feldman, 2001). Prostate tumor
growth is originally androgen dependent, however, regression of cancer after androgen
ablation therapy causes androgen independent prostate cancer to form, which is a more
lethal form of prostate cancer (Feldman and Feldman, 2001).
The total estimated prostate cancer cases in the United States for 2004 are
230,110 and the total estimated deaths are 29,900 (Ries et al., 2001). About 98% of
prostate cancers are adenocarcinomas that begin in the periphery and then infiltrate the
gland (Boissannault and Goodman, 2003; Wilson and Hillegas, 2003). Cell lines used in
this study that were adenocarcinomas were LNCaP the androgen responsive cell line
(Webber et al., 1997), and the androgen independent cell lines DU-145 and PC-3
14

(Webber et al., 1997). Current prognostic markers utilized for prostate cancer include
RNA and protein for the prostate specific antigen (Sidransky, 2002).

Breast Cancer
Normal anatomy of the breast consists of 15-25 lobes of glandular tissue, with
fibrous strands of connective tissue (stroma) separating the lobes as well as separating the
breast from the chest wall (Hillegas, 2003). Adipose tissue surrounds each glandular lobe
within the confines of the connective tissue (Hillegas, 2003). Estrogen is necessary for
proliferation of mammary cells and is believed to promote the proliferation of
transformed cells (Goodman, 2003b). Infiltrating ductal carcinoma is the most common
infiltrating breast cancer, which invades the stroma beyond the duct and can potentially
metastasize (Hillegas, 2003). Breast metastases occur through mammary ducts and
through internal mammary, axillary and supraclavicular lymph nodes (Hillegas, 2003).
About 80% of breast cancers are adenocarcinomas originating in the ducts or lobules of
the breast (Goodman, 2003b). The adenocarcinoma cell lines used in this study are
MDA-MB-231 (MDA), MCF-7, and T-47D (Burdall et al., 2003). Carcinosarcoma is
rare for breast cancers, and the Hs578T cell line used in this study is a carcinosarcoma
(Hackett et al., 1977). These cell lines were collected from pleural effusions, or drainage
of lymph fluid from metastases to the surrounding lymph nodes (Burdall et al., 2003;
Hackett et al., 1977). MDA and Hs578T are estrogen receptor negative cell lines and
MCF-7 and T-47D are estrogen receptor positive cell lines (Hackett et al., 1977; Burdall

et al., 2003).
The total estimated breast cancer cases for women in the United States for 2004
are 215,990 (Ries et al., 2004). Breast cancer is the second most common cancer for
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women, and is the leading cause of cancer deaths (Hillegas, 2003). Although diagnosing
whether a breast lesion is benign, pre-cancerous or cancerous has become more straight
forward, determining the prognosis for patients with cancerous lesions is not well
defined. Often cancer patients are treated with aggressive chemotherapy and radiation
when many do not need such aggressive treatment simply due to the lack of reliable
prognostic markers. Therefore, many proteins are screened for expression relative to
patient outcome in attempts to identify good prognostic markers. The EGF receptors
(EGFR, ErbB2, ErbB3) are involved in mammary gland development and are over
expressed in breast cancer (Stern, 2000). The potential prognostic marker gene in breast
cancer, Epsl5, is down-regulated in patients with short survival (Amatschek etal., 2004).
DNA microsatellite alterations, RNA cytokeratins, and hypermethylation of the BRCA1
gene are also prognostic markers (Sidransky, 2002). Estrogen receptor positive
expression in breast cancers is an important initial determinant of prognosis; its
expression determines the amount and type (usually aggressive) of therapy a patient will
receive. Overexpression of the estrogen receptor E R a is an excellent initial predictive
factor, although it has been positively correlated with a good prognostic outcome
diminishing its status as an independent prognostic marker (Esteva and Hortobagyi,
2004). While systemic therapy improves early ER positive breast cancer survival of
those patients (Esteva and Hortobagyi, 2004), the therapy can be toxic to those patients
who do not need the aggressive approach in treating their cancer.

Statement o f Hypothesis
BOG25 and 7a5 contain a unique domain combination of the EH-Network family
of endocytosis, intracellular signal transduction and cell fate determination proteins and
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of the death domain family of proteins. All domains except the death domain are
contained within the EH-Network family of proteins.
Since cancers are known to promote growth and resist apoptosis, the working
hypothesis for the current study is that the BOG25 family of proteins are important to the
cancer phenotype and therefore, will exhibit a substantial differential expression between
some cancer cell lines and/or normal cell lines if they are important to the cancer
phenotype.
To test this hypothesis, bladder, prostate, and breast cell lines were screened for
BOG25 and 7a5 protein expression and based on preliminary results, breast cell lines
were examined further for determination of subcellular localization and message levels.
Several research questions were addressed including: Are there differences in protein
expression and/or message levels between normal and cancerous cells or between
cancerous cell lines? Is there a subcellular localization re-distribution of BOG25 proteins
between normal and cancerous cells or between cancerous cell lines? These fundamental
questions are scientifically important as changes in intracellular localization, message
levels and/or protein levels of BOG25 and 7a5 proteins may give important insight into
their potential as prognostic cancer markers.
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CHAPTER II
MATERIALS AND METHODS
To answer the hypothesis-driven questions regarding differences in protein
expression, message levels and the subcellular localizations for BOG25 and 7a5, multiple
techniques were used. Cell culture was critical for both protein and message analyses.
Protein levels were determined using Western blot analyses, which included
determination of total protein concentrations for cell lysates. The subcellular
fractionation technique was chosen based on studies in the lab, and is the NE-PER
protocol from Pierce. RT-PCR was critical in confirming the predicted 7a5 cDNA
sequence that involved subcloning and sequencing portions of amplified 7a5. RT-PCR
was also important for determining message levels from total RNA isolated from the cell
lines and were compared to corresponding protein levels. Primers for RT-PCR were
engineered to specifically amplify BOG25 or 7a5 without cross-reacting with these
similar sequences. All PCR products were visualized on agarose gels.

Cell Culture
Cell lines were obtained from Dr. Don Sens (Professor of Surgery, UND School
of Medicine and Health Sciences Grand Forks, ND). Breast cell lines include: normal
breast epithelial cells: MCF-10; estrogen receptor negative (ER') cells: MDA-MB-231
and Hs578T; and estrogen receptor positive (ER^) cells: MCF-7 and T-47D. Bladder cell
lines include: normal bladder epithelial cells: UROtsa; three levels of transitional cell
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carcinoma cells: high-grade HTB 1, papillary low-grade HTB 2, and metastatic highgrade HTB 5; and carcinoma cells: CRL-1472. Prostate cell lines include normal prostate
epithelial cells: RWPE; androgen responsive cells: LNCaP; and androgen independent
cells: DU-145 and PC-3. Cells were maintained in growth medium until confluence in T75 or T-25 flasks and were usually harvested 24 hours after the last medium change.

Total Cell Lysates
Total cell lysate controls were collected by rinsing cells with phenol red free
Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 (Ham) (1:1) (Gibco,
Carlsbad, CA or Hyclone Laboratories, Logan, UT), then lysing the cells with 2%
Sodium Dodecyl Sulfate (SDS) in Phosphate Buffered Saline (PBS) with 3mM M gCh,
ImM EGTA, lOmM Na pyrophosphate, lOmM orthovanadate, 50mM NaF and Complete
EDTA protease inhibitors (Roche Applied Science, Indianapolis, IN). Lysates were
sonicated briefly, ~3-5 sec, and stored at -20°C.

Determination o f Total Protein Concentration
Total protein concentration was determined using the BCA assay (Pierce,
Rockford, IL). Briefly, a range of bovine serum, albumin (BSA) standards, Opg to
2000pg, were prepared, and cupric-sulfate buffer reagent was added to cell lysates, cell
fractions and standards. All samples were incubated at 37°C for 30 min. Protein
concentration was determined for some samples under an enhanced protocol: BSA
standard range was Opg -300pg and samples and standards were incubated at 60°C for 30
min. Absorbance was determined at 562nm for all samples on a spectrophotometer.
Total protein concentrations were determined relative to pg of BSA standard using GBStat PPC 6.5.6 software (Dynamic Microsystems, Silver Springs, MD).
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Western Blot Analysis
In SDS-PAGE and Western blot analyses, all samples were adjusted to 2% SDS,
loaded by equal volume and run under reducing conditions on 4-12% Bis-Tris NuPAGE
gels with MOPS running buffer using the NuPAGE system (Invitrogen, Carlsbad, CA).
Pre-stained Broad Range SDS Standards, (BioRad Laboratories, Hercules, CA) were
used as markers. Gels were transferred onto a 0.45 pM nitrocellulose membrane, also
under reducing conditions, using the NuPAGE system (Invitrogen, Carlsbad, CA).
Blots were blocked in 5% milk in PBS-0.5% Tween 20 followed by incubation in
chicken anti-human BOG25 IgY primary antibody or chicken pre-immune IgY antibody
(Aves Laboratories, Tigard, OR), each diluted 1:10,000 in 1% milk in PBS. The blots
were rinsed with PBS-0.5% Tween 20, followed by incubation with anti-chicken IgY
secondary antibody conjugated with horseradish peroxidase (Aves Laboratories, Tigard,
OR) diluted 1:10,000 in 1% milk in PBS. Blots were rinsed with PBS-0.5% Tween 20.
The ECL Western Kit was used for chemiluminescent detection and blots were exposed
to Hyperfilm ECL™ (Amersham Pharmacia Biotech, Piscataway, NJ). Protein bands
were quantitated by scanning Western blot films followed by analysis with NIH Image
1.62 software to determine Integrated Optical Density (IOD) for each band. Data were
graphed relative to pg total protein using DeltaGraph software (SPSS Inc, Chicago, IL) or
GB Stat PPC 6.5.6 software (Dynamic Microsystems, Silver Springs, MD).

Subcellular Fractionation
Nuclear (NF) and postnuclear fractions (PNF) were obtained using the NE-PER
nuclear and cytoplasmic extraction kit (Pierce, Rockford, IL). Cells were trypsinized
with 0.25% trypsin-EDTA (Invitrogen, Carlsbad, CA) until rounded, resuspended in
20

DMEM-F12 supplemented with 10% fetal bovine serum (FBS) and centrifuged at 800
rpm for 10 min at 4 C. Cells were resuspended in DMEM-F12 without phenol red, 4 x
106 cells were aliquotted, re-centrifuged at 800 rpm for 10 min at 4 C, and resuspended in
192pl CERI plus protease inhibitors followed by incubation on ice for 10 min. 11 pi of
CERII was added followed by vortexing and incubation on ice for 1 min. Samples were
re-vortexed and centrifuged at 2000 g for 10 min at 4°C. The supernatant, containing the
PNF, was then re-centrifuged twice. Likewise, the nuclei pellet was washed twice in
96pl CER I with protease inhibitors plus 5.5pl CER II, followed by resuspension in 96pl
NER with protease inhibitors and vortexing 15 sec every 10 min over 40 min. The nuclei
were then centrifuged at 16,000 g for 10 min at 4 =C. All samples were desalted using
protein desalting spin columns (Pierce, Rockford, IL) and adjusted to 2% SDS before
being analyzed by Western blot.

RNA Isolation
Total RNA was isolated from cells grown in monolayer cultures using TRI
reagent (Molecular Research Center, Inc, Cincinnati, OH). Cells were lysed with TRI
reagent, and incubated at 25 C for 5 min. l-bromo-3-chloropropane was added to TRI
reagent samples, vigorously mixed for 15 sec, incubated at 25°C for 15 min, and
centrifuged 12,000 g for 15 min at 4 C. The aqueous phase was collected, 1/2 TRI
reagent volume of isopropanol was added, mixed, incubated at 25°C for 10 min and then
incubated at -20 C for a minimum of 16 hours. Samples were centrifuged at 12,000 g for
8 min at 4 C. The pellet containing total RNA was washed twice with 75% ethanol and
centrifuged at 7500 g for 5 min at 4 C. RNA was solubilized in 600pl MilliQ water/T-75
flask, or 90pl MilliQ water/T-25 flask and stored at -80°C.
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RNA Primers
Specific primers for BOG25, 7a5, and glyceraldehyde-3-phosphate
dehydrogenase (G3PDH) were designed using MacVector 6.5.3 Software (Accelrys Inc,
San Diego, CA) and synthesized at MWG Biotech Corp. (High Point, NC) (Table 1).
Primers were reconstituted in MilliQ water and stored at -20°C.
Table 1: Primers for RT-PCR. Table 1 displays primer sequences for BOG25, 7a5 and
G3PDH, and expected amplification size.

PRIMER

PRIMER SEQUENCE

PRODUCT SIZE

Forward = top Reverse = bottom

(bp)

BOG2 5

5 ' -TTCCTCACGTACATCTATGCCTC-3'
5 ' -ATCTGCTGCTTGGAGACCTTGG-3'

370

7 a 5 N -T erm

5 ' -CCCATTTTTGGATGACATAACTCA-3'
5 ' -GGGCATGTGCTGTGTCGTCTA-3 '

236

7 a 5 C -Term

5 ' -TAGCTGATGTCCTGGGTTACTCAC-3 '
5 ' -ATCTCCAGTGTTTCCTCGATGA-3'

335

7 a 5 M id

5 ' -TGATTTTTGTGTTCAAGTGGAGCC-3 '
5 ' -GCTTTTACCTTACCTCCGAG-3'

315

G3PDH

5 ' -TGCCCTCAACGACCACTTTG-3'
5 ' -GATGGTACATGACAAGGTGCGG-3'

283

Reverse Transcription
Reverse transcription (RT) reactions were performed under the following
conditions: 5.0mM MgCl2; IX PCR Buffer II; 1 OmM each dATP, dTTP, dCTP, dGTP;
l.OU/pl RNase Inhibitor; 2.5U/pl MuLV Reverse Transcriptase; 2.5 pM random hexamer
primer; 0.75 pg total RNA or 0.3 pg for N and C termini sequencing, and 0.5 pg for
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Mid. Thermocycler conditions were 25°C, 10 min; 42 C, 20 min; denature at 99 C, 5 min
at 1 cycle; and stored at 4°C.

Polymerase Chain Reaction
Polymerase chain reaction (PCR) conditions were; lOpl RT reaction in 50 (ul final
volume of: 2.0mM MgCU, IX PCR Buffer II; 2.5U/100pl AmpliTaq DNA Polymerase;
0.2mM each dATP, dTTP, dCTP, dGTP; and 2.5pM of each primer. Thermocycler
conditions were: 95°C, 2 min; 95°C, 45 sec; 52°C, 45 sec; 72°C, 45 sec for 40 cycles for
BOG25 and 7a5 and 35-37 cycles for G3PDH.

Agarose Gels
lOpl of each PCR reaction was mixed with Gel Loading Solution (Sigma-Aldrich,
St. Louis, MO), and electrophoretically separated on a 1.5% agarose gel in Tris-Acetic
Acid-EDTA (TAE) buffer. Gels were stained and destained with ethidium bromide (0.05
pg/ml Fisher Scientific, Pittsburgh, PA). 0.5 pg each of <j>x/HAE III fragments and
LDNA/HIND III fragments (Invitrogen, Carlsbad, CA), were used as markers. Amplified
DNA bands were quantitated by digitally capturing images of agarose gels using an
Ultraviolet Transilluminator, and a Kodak EDAS 290 camera with Kodak ID 3.5.3 LE
USB software. Bands were quantitated and an IOD for each DNA band was determined
using NIH Image 1.62 software and determining. Data were plotted as IOD of BOG25 or
7a5 or relative to IOD of G3PDH using DeltaGraph 4.5 software (SPSS Inc, Chicago,
IL).

Subcloning and Sequencing
Subcloning of RT-PCR products was performed using the PCR-TRAP Cloning
System (GenHunter Corp., Nashville, TN). Briefly, 5.0 or 10.0 pi of RT-PCR product
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was subcloned into the PCR-TRAP vector at 16°C overnight followed by transformation
into GH Competent cells. Transformed bacteria were plated onto tetracycline agar plates
and grown overnight at 37°C. Colonies containing the correct insert were determined by
PCR using the vector-specific Lgh and Rgh primers followed by growth in 5 ml cultures.
Plasmid DNA purification was performed using the Wizard Plus DNA Purification
System (Promega Corp., Madison WI) and plasmid concentration was determined using
absorption 260/280 nm on a spectrophotometer. Sequencing of plasmid DNA was
performed at MWG Biotech Corp. (High Point, NC) using the vector-specific Lseq and
Rseq primers. All sequencing alignments were performed using MacVector 6.5.3
Software (Accelrys Inc., San Diego, CA).
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CHAPTER III
RESULTS
Preliminary BOG25 and 7a5 Protein Expression

Western Blot Analysis
The working hypothesis of this study is that the BOG25 and 7a5 proteins are
important to the cancer phenotype, and therefore, will exhibit a substantial difference in
expression between the cancer cell lines and/or between the cancer and normal cell lines.
Substantial differential expression includes a much higher level of expression of a
cancerous cell line to the normal and/or another cancerous cell line. To characterize the
levels of BOG25 family of proteins, total cell lysates from bladder, prostate and breast
cell lines were analyzed. Based on preliminary results, breast cell lines were chosen for
further study with subcellular fractionation and mRNA analyses to determine if the
BOG25 proteins had subcellular localization differences and for alterations in mRNA
levels with respect to corresponding protein levels.
Cell lysates from a series of bladder cell lines that included immortalized normal
urothelial cell line UROtsa, and transitional cell carcinomas HTB 1, HTB 2, HTB 5 and
CRL-1472 were collected and analyzed by Western blot using a polyclonal BOG25 IgY
antibody that detects both BOG25 and 7a5 (Figure 3 A). BOG25 and 7a5 proteins were
detected at the molecular weights of 120kD, and lOOkD, respectively. Compared to the
other bladder cell lines, HTB 2 cells had the lowest intensity of BOG25 and 7a5 was
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Figure 3: Western blot and analysis of BOG25 and 7a5 proteins from bladder cell lines.
(A) Lysates from bladder normal cell line UROtsa, and cancerous cell lines HTB 1, HTB
2, HTB 5 and CRL 1472 were immunoblotted using a chicken anti-human BOG25
antibody. Levels of BOG25 (B) and 7a5 (C) proteins were quantitated from total cell
lysates and are shown as IOD/pg total protein with fold level differences in comparison
to the cell line with the lowest protein expression above each bar.
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barely detectible in this cell line. BOG25 bands in HTB 1 and HTB 5 cell lines were
more intense than the other cell lines. Additionally, the 7a5 band appeared very intensely
in the HTB 5 cell line compared to all the other bladder cell lines. Western blot data
were quantitated and shown as Integrated Optical Density (IOD) per p.g total protein
(Figure 3 B and C). Quantitation of BOG25 from the immunoblot showed that the HTB
5 cell line expressed the highest level of BOG25, with 6.5-fold more than the CRL-1472
cell line (Figure 3 B). In addition, HTB 5 cells expressed a very high level of 7a5
protein, 39-fold more than HTB 2 cells (Figure 3 C). The HTB 2 cell line had a low level
of expression of 7a5, 17- and 11-fold less than UROtsa and HTB 1 cell lines,
respectively. Among the bladder cell lines, the 7a5 protein expressed a substantial
difference in the most advanced cancer cell line, HTB 5.
Similarly, cell lysates from a series of prostate cell lines including an
immortalized normal cell line RWPE, an androgen responsive adenocarcinoma LNCaP,
and 2 androgen-independent adenocarcinomas D U -145 and PC-3 were collected and
analyzed by Western blot analysis using the polyclonal BOG25 IgY antibody that detects
both BOG25 and 7a5 (Figure 4 A). Examination of the immunoblot showed that the
LNCaP cell line had the lowest band intensity for both BOG25 and 7a5 proteins.
Western blot data were quantitated and are shown as IOD per p,g total protein (Figure 4 B
and C). BOG25 was expressed at slightly lower levels in all three of the cancerous cell
lines, with LNCaP expressing the lowest at 2.5-fold less than the normal cell line, RWPE
(Figure 4 B). Quantitation of 7a5 showed that LNCaP also had the lowest expression,
almost 6 -fold less than the cancer cell lines D U -145 and PC-3 (Figure 4 C). However, a

27

A.
BOG25

7a5

RWPE

LNCaP

D U -145

PC-3

B. BOG25
0.4

RWPE

LNCaP

DU-145

PC-3

RWPE

LNCaP

DU-145

PC-3

Figure 4: Western blot and analysis of BOG25 and 7a5 proteins from prostate cell lines.
(A) Lysates from prostate normal cell line RWPE, and cancerous cell lines LNCaP, DU145 and PC-3 were immunoblotted using a chicken anti-human BOG25 antibody. Levels
of BOG25 (B) and 7a5 (C) proteins were quantitated from total cell lysates. Levels of
BOG25 and 7a5 are shown as IOD/jig total protein with fold level differences above each
bar.
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substantial protein expression difference was not observed with either BOG25 or 7a5 in
the prostate cell lines.
Total cell lysates from a series of breast cell lines including an immortalized
normal breast cell line MCF-10, cancerous estrogen receptor negative cell lines MDA
and Hs578T, and cancerous estrogen receptor positive cell lines MCF-7 and T-47D were
collected and analyzed by immunoblot using the BOG25 IgY antibody that detects both
BOG25 and 7a5 (Figure 5 A). Hs578T exhibited a very intense BOG25 band that
appeared almost as intensely as the 7a5 band. Western blot data were quantitated and
shown as IOD per pg total protein (Figure 5 B and C). Quantitation, using an average of
two experiments, showed that Hs578T cells had a 14-fold higher expression level of
BOG25 than MCF-7 cells (Figure 5 B). The normal cell line MCF-10, and cancerous cell
lines MDA, MCF-7 and T-47D expressed BOG25 at a much lower level than Hs578T
(Figure 5 B). Quantitation of the immunoblot also showed that Hs578T expressed 7a5 at
almost 4-fold higher than MCF-7, however, no substantial protein expression difference
was observed with 7a5 in the breast cell lines (Figure 5 C). Among the breast cell lines,
the BOG25 protein expressed a substantial difference in the most advanced cancer cell
line, Hs578T.
These preliminary data show that all breast, bladder and prostate cell lines
examined expressed both BOG25 and 7a5 proteins. However, some cancer cell lines
such as Hs578T and HTB 5 expressed very high levels of BOG25 and 7a5, respectively,
while other cancer cell lines such as MCF-7 and HTB 2 expressed low levels of both
BOG25 and 7a5 (Table 2). Hs578T expressed a substantial differential of BOG25, a
level much higher than both the normal and other cancerous cell lines. Based on these
29

A.
120kD

MCF-10

MDA

Hs578T

B. BOG25

MCF-7

T-47D

C. 7a5
16
14

■512
£ 10

1 “
g 6
1

^

4.0

3.9

22

2

0

1.0

M CF-10

MDA

H S578T

M CF-7

T-47D

Figure 5: Western blot and analysis of BOG25 and 7a5 proteins from breast cell lines.
(A) Cell lysates from breast normal cell line MCF-10, and cancerous cell lines MDAMB-231 (MDA), Hs578T, MCF-7 and T-47D were immunoblotted using a chicken anti
human BOG25 antibody. Levels of BOG25 (A) and 7a5 (C) proteins were quantitated
from lysates of two separate experiments and are shown as the average from two separate
experiments in IOD/pg total protein. Fold level differences are shown above each bar.
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Table 2: Results Summary. The ratio of the lowest expresser to highest expresser for
BOG25 and 7a5 protein is shown for each cell culture system.

B la d d e r
HTB 2: HTB 5

P r o s ta te
LNCaP: PC-3

B re a st
MCF-7: Hs578T

BOG25

1:7

1 :2

1 : 14

7a5

1 : 39

1:6

1 :4

results, the breast cell lines were further characterized for differences in subcellular
distribution of the BOG25 proteins and for differences in message levels of BOG25 and
7a5.
Subcellular Distribution and Message Levels of BOG25 and 7a5 in Breast Cell Lines

Subcellular Fractionation
The hypothesis that Hs578T cells, which express very high levels of BOG25,
would distribute more BOG25 in either the nucleus or plasma membrane compared to the
to the other breast cell lines was tested using subcellular fractionation. The NE-PER
reagent protocol was used to determine the subcellular localization of BOG25 and 7a5
proteins. Post-nuclear fractions (PNF) consisted of non-nuclear membranes and cytosol,
and nuclear fractions (NF) contained the nuclear membrane and contents within the
nucleus. All fractions were adjusted to 2% SDS, electrophoretically separated on a 412% Bis-Tris gel and immunoblotted with the BOG25 IgY antibody that detects both
BOG25 and 7a5 (Figure 6 A). Subcellular fractionation was performed twice using two
separate sets of cell cultures and results from both experiments are shown in Figure 6 (B-
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Figure 6 : Western blot and analysis of the subcellular localization of BOG25 and 7a5
proteins from breast cell lines. (A) Post-nuclear fractions (PNF) contain membranes and
cytosol. Nuclear fractions (NF) contain the nuclear membrane and nuclear contents.
PNF and NF were isolated from breast normal cell line MCF-10, and cancerous cell lines
MDA-MB-231 (MDA), Hs578T, MCF-7 and T-47D using the NE-PER reagent and
detected with the chicken anti-human BOG25 antibody. This experiment was performed
twice on separate sets of cell cultures. Levels of BOG25 (B and D) and 7a5 (C and E)
proteins in PNF (black bar) and NF (grey bar) were quantitated for each experiment.
Levels of BOG25 and 7a5 are shown as IOD/pg total protein with fold level differences
above each bar.
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E). Although BOG25 NF bands were faint, the immunoblot showed that both BOG25and
7a5 proteins were found in the NF and PNF in all breast cell lines. Hs578T
expressed BOG25 at the highest intensity in both the PNF and the NF. Additionally, it
was noted that 7a5 nuclear fractions migrated higher on the Western blot than the
respective PNF and appeared to contain a doublet band in all breast cell lines. These
Western blot data were quantitated and are shown as IOD per pg total protein (Figure 6
B-E). Quantitation of BOG25 showed expression at approximately a 1:1 ratio of PNF to
NF in all breast cell lines including Hs578T cells (Figure 6 B and D). Quantitation of the
immunoblot also showed that the 7a5 protein was expressed at higher levels in the NF
than PNF in all cell lines (Figure 6 C and E). No substantial alteration in subcellular
localization was observed for either BOG25 or 7a5, and the Hs578T cell line distributed
BOG25 and 7a5 similarly to the other breast cell lines (Figure 6 B-E).

7a5 RT-PCR, Subcloning and Sequencing
7a5 was identified by the Human Genome Project as a putative protein similar to
BOG25. To confirm that 7a5 mRNA was being transcribed, RT-PCR amplification of 3
regions o f the 7a5 coding region including the N-term, Mid and C-term were amplified
from total RNA isolated from the retinal pigment epithelial cell line, ARPE-19, and from
Hs578T breast cancer cells, followed by subcloning and DNA sequencing. 7a5-specific
primers were selected based on the reported genomic sequence and were synthesized by
MWG Biotech Corp. Reverse transcription reactions were performed using 0.3 pg of
total RNA for the N-term and C-term regions, and 0.5 pg of total RNA for the Mid region
and random hexamer primers. PCR reactions were then performed using the 7a5 specific
primers (See Table 1 in Materials and Methods). RT-PCR products were
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electrophoretically separated on agarose gels and visualized using ultraviolet light to
identify cDNA banding patterns (Figure 7). The 7a5 N-Term segment contains 236 base
pairs (bp) and amplified to the predicted size (Figure 7 A, Lane 4). The 7a5 N-Term
segment is located within exon 2 , and reverse transcriptase minus and plus conditions
(Figure 7 A, Lanes 3 and 4 respectively) were run to determine if the amplified product
could have been generated from the presence of contaminating genomic DNA. Since the
236 bp-band was not seen in the minus RT- reaction (Figure 7 A, Lane 3), the PCR
product in the RT plus reaction was most likely amplified from 7a5 mRNA. The 7a5 CTerm segment spans exons 2 and 3 and the correct size product would most likely be
from cDNA and not contaminating genomic DNA. The C-Term segment contains 335 bp
and amplified to the correct, predicted size (Figure 7 A, Lane 1). Likewise, the 7a5 Mid
segment contains 315 bp and amplified to the predicted size (Figure 7 B, Lane 1). The
7a5 Mid segment is also located within exon 2, and no visible band was amplified in the
minus reverse transcriptase reaction (Figure 7 B, Lane 3). The RT-PCR 7a5 N-Term, Mid
and C-Term products were then individually subcloned into the PCR-TRAP vector, and
purified plasmid DNA was sequenced at MWG Biotech Corp. ARPE-19 samples
displayed the strongest amplified products for the 7a5 segments and therefore, these
samples were used for subcloning and sequencing. The sequence for each 7a5 segment
was aligned to the sequence submitted by the Human Genome Project and was found to
match the predicted coding region within the genomic sequence with 100 % identity
thereby confirming about 36% of the 7a5 open reading frame (Figure 8 A-C). The
regions of 7a5 that have been cDNA sequenced are shown relative to the aligned amino
acid sequence of 7a5 to an N-terminal truncated BOG25 sequence (Figure 9). The amino
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Figure 7: RT-PCR of 3 regions of 7a5 (N-Term, Mid and C-Term) using total RNA
isolated from ARPE-19 cells. (A) 7a5 C-Term segment is seen in lane 1, and 7a5 NTerm in lane 4. Reverse transcriptase minus and plus conditions for N-terminus are in
lanes 3 and 4, respectively. (B) Reverse transcriptase enzyme plus and minus conditions
for 7a5 Mid segment are shown in lanes 1 and 3 respectively. The Molecular weight
markers (|)x/HAE III and ADNA/HIND III were run in lane 2 (A and B).
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Figure 8 : 7a5 cDNA alignment. 7a5 N-Term (A), Mid (B) and C-Term (C) clones were
sequenced and aligned to the predicted coding region of the 7a5 gene. The subcloned
cDNA sequences matched the 7a5 gene sequence with 100% alignment. The top two
rows show the double strand base pairing of the subcloned sequences. Below, the
genomic sequence (predicted 7a5 cDNA) is aligned with the subcloned cDNA sequence.
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Figure 9: 7a5 homology to BOG25. The 7a5 amino acid sequence (top) exhibits 60%
similarity and identity (gray boxed regions) to the truncated (A) BOG25 amino acid
sequence (bottom). The last 2.5 rows contain the death domain and have an even higher
amino acid homology. The N-terminus including the SH3 domain of BOG25 is not
shown. The sequenced 7a5 N-Term, 7a5 Mid-sequence and 7a5 C-Term segments are
shown with a black bar above each region.
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acid sequence of 7a5 aligns to BOG25 amino acid sequence with 60% similarity and
identity (Figure 9, gray boxed regions). The death domain is located on the last 2.5 lines
with an even higher homology of 7a5 to BOG25 (Figure 9).

mRNA and Corresponding Protein Levels o f BOG25 and 7a5 In Breast Cell Lines
The hypothesis that breast cells would exhibit similar mRNA and corresponding
protein levels of BOG25 and 7a5 was tested by comparing triplicate mRNA samples, and
triplicate protein samples. Six flasks were used to generate triplicate total RNA and total
cell lysates. TRI reagent was used to isolate total RNA from cells grown in monolayer
cultures and 2% SDS buffer was used to obtain cell lysates from corresponding cultures.
BOG25, 7a5 and glyceraldehyde-3-phosphate dehydrogenase (G3PDH) message levels
were amplified by RT-PCR and electrophoretically separated on 1.5% agarose gels
(Figure 10 A-C). Reverse transcription amplification was performed using 0.75 p.g total
RNA and random hexamers, followed by 7a5 N-Term, BOG25 and G3PDH specific
primers (See Table 1 in Materials and Methods). Since the 7a5 N-Term amplification
was consistently detected as a high intensity band compared to the C-Term and Mid
reactions, the N-term primer set was chosen for 7a5 amplification. G3PDH, a
constitutively active gene, was used as a control. G3PDH spans multiple exons and
therefore, should not amplify a 283 bp band if amplified from contaminating genomic
DNA. The BOG25 primer set spans exons 4-5 while the 7a5 primer set is within exon 2.
Therefore, a minus RT- reaction was run as a control to determine if the amplified
products could have been generated from contaminating genomic DNA (Figure 10 D).
Since no bands were seen in the minus RT reaction, the PCR products for G3PDH,
BOG25 and 7a5 most likely did not originate from contaminating genomic DNA.
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Figure 10: RT-PCR of G3PDH, BOG25 and 7a5. G3PDH, BOG25 and 7a5 were
amplified from each breast cell lines in triplicate (A-C) using RT-PCR. Breast cell lines
included: normal MCF-10 (Lanes 6 , 11, 16), and cancerous MDA (Lanes 5,10,15),
FIs578T (Lanes 4, 9, 14), MCF-7 (Lanes 3, 8 , 13) and T-47D (Lanes 2, 7, 12). Lane 1
contains (fix/HAE III and XDNA/HIND III molecular marker. Reverse transcriptase
minus reaction for Flask 1 RNA preparations are shown in (D).
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Additionally, the optimum cycles for the control, G3PDH, were determined to be 3537cycles, and the cycles for BOG25 and 7a5 were optimum at 40 cycles each. In order to
compare mRNA levels to protein levels, cell lysates from corresponding triplicate protein
preparations were collected and analyzed by Western blot using the polyclonal BOG25
IgY antibody that detects both BOG25 and 7a5 (Figure 11).
Correct size bands were always detected for the G3PDH control in all cell lines
(Figure 10). Band intensities showed subtle differences among cell lines. Bands on the
agarose gels were quantitated and are shown as IOD (Figure 12 A-C). Only subtle
differences were seen among the cell lines in all 3 flasks. G3PDH data were normalized,
averaged and shown as IOD in Figure 12 D. The averaged data of G3PDH showed only
very subtle differences between the cell lines and triplicate flasks.
BOG25 RT-PCR resulted in a 370 bp band from all 3 Hs578T samples, and
BOG25 was amplified from MDA samples in two out of three flasks. The other cell lines
never amplified a detectable BOG25 370 bp band. BOG25 bands on the agarose gels
were quantitated and shown as IOD (Figure 13 A-C). The 3 samples of Hs578T
expressed a high level of BOG25 message, whereas the two samples of MDA expressed a
moderate level of BOG25 message, compared to the cell lines MCF-10, MCF-7 and T47D. Triplicate BOG25 mRNA data were normalized, averaged and shown as IOD
(Figure 14 A). Measurements for MCF-10, MCF-7 and T-47D reflect background as
there were no visible bands for these cell lines. Data are reported as averages from the
individual flasks. The average BOG25 mRNA level for Hs578T was very high, and the
level for MDA was moderate, compared to the cell lines MCF-10, MCF-7 and T-47D.
When averaged BOG25 mRNA data is shown relative to the average of the constitutively
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Figure 11: Western blots of BOG25 and 7a5 proteins from total cell lysates. Cell lysates
in normal breast cell line MCF-10, and cancerous breast cell lines MDA-MB-231
(MDA), Hs578T, MCF-7 and T-47D were immunoblotted in triplicate (A-C) using a
1:10,000 dilution of chicken anti-human BOG25 antibody.
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Figure 12: mRNA analysis of G3PDH. RT-PCR was used to determine levels of G3PDH
mRNA from triplicate total RNA preparations from breast cell lines: normal cell line
MCF-10, and cancerous cell lines MDA-MB-231 (MDA), Hs578T, MCF-7 and T-47D.
Levels of G3PDH are shown as IOD (A-C). Triplicate G3PDH data were normalized,
averaged and graphed as IOD (D). Fold level differences are shown above each bar.
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B. BOG25 mRNA Flask 2

E. BOG25 Protein Flask 2

C. BOG25 mRNA Flask 3

F. BOG25 Protein Flask 3

Figure 13: mRNA and protein analysis of BOG25. RT-PCR was used to determine levels
of BOG25 mRNA from triplicate total RNA preparations from breast cell lines: normal
cell line MCF-10, and cancerous cell lines MDA-MB-231 (MDA), Hs578T, MCF-7 and
T-47D. Levels of BOG25 mRNA are shown as IOD (A-C). Corresponding triplicate
flasks of BOG25 protein (D-F) were quantitated from lysates of breast cell lines and are
shown as IOD/pg total protein. Fold level differences are shown above each bar.
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Figure 14: BOG25 average mRNA and protein analyses. BOG25 mRNA (A) and protein
(B) were reported as the average from 3 individual flasks. Averaged BOG25 (C) mRNA
are shown relative to G3PDH. mRNA levels are shown as IOD and protein levels are
shown as IOD/pg total protein. Fold differences are shown above each bar.
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active G3PDH, the BOG25 mRNA level was very high in Hs578T compared to all the
other cell lines (Figure 14 B).
Corresponding immunoblots revealed that a 120 lcD BOG25 band was expressed
by all cell lines (Figure 11). However, compared to the other breast cell lines, BOG25
protein expression was highest in Hs578T cells. BOG25 Western blot data were
quantitated and are shown as IOD per p,g total protein (Figure 13 D-F). BOG25 protein
levels in the breast cell lines were similar quantitatively to the mRNA levels from the
corresponding cell line. Hs578T expressed a much higher level of both BOG25 protein
and mRNA than all other cell lines. Triplicate BOG25 protein data were normalized,
averaged and shown as IOD per fig total protein (Figure 14 C). The average BOG25
protein level for Hs578T was much higher than all other cell lines, similar to mRNA
levels where all other cell lines expressed BOG25 at a lower level than Hs578T.
7a5 RT-PCR resulted in a 236 bp band that amplified correctly to the expected
size in MCF-10, Hs578T, MCF-7, and T-47D cell lines. The correctly-sized 7a5 band
was detected only once in MDA, where the other two flasks revealed a faint band at
about 900 bp that could not be subcloned or re-amplified (Figure 10 A and C). Only the
236 bp band for the MDA cell line was quantitated. 7a5 bands on the agarose gels were
quantitated and shown as IOD (Figure 15 A-C). The 7a5 mRNA level in the MDA cell
line was lowest compared to all other cell lines, which expressed similar 7a5 mRNA
levels. Triplicate 7a5 mRNA data were normalized, averaged and shown as IOD (Figure
16 A). The averaged 7a5 level in the MDA cell line appeared substantial, but the level
difference was due to the inability to amplify a 236 bp product from the 7a5 message in 2
of the 3 samples. Averaged 7a5 mRNA levels were similar to the levels in individual
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Figure 15: mRNA and protein analysis of 7a5. RT-PCR was used to determine levels of
7a5 mRNA from triplicate total RNA preparations from breast cell lines: normal cell line
MCF-10, and cancerous cell lines MDA-MB-231 (MDA), Hs578T, MCF-7 and T-47D.
Levels of 7a5 mRNA are shown as IOD (A-C). Corresponding triplicate flasks of 7a5
protein (D-F) were quantitated from lysates of breast cell lines and are shown as lOD/pg
total protein. Fold level differences are shown above each bar.
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Figure 16: 7a5 average mRNA and protein analyses. 7a5 mRNA (A) and protein (B)
were reported as the average from 3 individual flasks. Averaged 7a5 (C) mRNA are
shown relative to G3PDH. mRNA levels are shown as IOD and protein levels are shown
as IOD/pg total protein. Fold differences are shown above each bar.
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samples where 7a5 was shown to be lowest in MDA, in contrast to the other cell lines,
which showed similar levels of 7a5 mRNA. When averaged 7a5 mRNA data is shown
relative to the constitutively active G3PDH, only minor differences were seen among
MCF-10, Hs578T, T-47D and MCF-7 (Figure 16 B).
Corresponding immunoblots revealed that a lOOkD 7a5 band was expressed by all
cell lines (Figure 11). All cell lines showed similar 7a5 band intensities on the
immunoblot. 7a5 triplicate protein Western blot data were quantitated and are shown as
IOD per pg total protein (Figure 15 D-F). The individual flask data of 7a5 showed only
subtle differences among cell lines. Triplicate 7a5 protein data were normalized,
averaged and shown as IOD per pg total protein (Figure 16 C). Averaged 7a5 protein
data showed subtle differences among cell lines and were similar to mRNA levels except
that protein and message levels did not correlate within the MDA cell line, where RTPCR amplification of the correct size band was inconsistent.
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CHAPTER IV
DISCUSSION
The hypothesis of this study is that the BOG25 and 7a5 proteins are important to
the cancer phenotype, and therefore, will have a substantial difference in expression
between the cancer cell lines and/or between the cancer and normal cell lines. Moreover,
with such differences in expression one would expect to observe changes in subcellular
localization and message levels reflective of levels in protein expression. BOG25 and
7a5 expression has never been examined in cancer. To characterize the levels of BOG25
family of proteins, total cell lysates from bladder, prostate and breast cell lines were
analyzed. Breast cell lines were further characterized by subcellular fractionation to
determine subcellular localization differences of BOG25 and 7a5, and RT-PCR was
employed to investigate alterations in mRNA levels of BOG25 and 7a5 with respect to
total protein levels.
Bladder cell lines did not show a substantial difference in BOG25 protein
expression. However, a substantial 7a5 protein expression among the cancer cell lines
was observed with a 39-fold increase in 7a5 in HTB 5 cells compared to HTB 2 cells.
Since HTB 5 cells are from an invasive, high-grade metastatic transitional cell carcinoma,
7a5 protein expression in this type of bladder cancer cell line indicated a correlation with
advancement in cancer stage.
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Prostate cell lines expressed only subtle differences in BOG25 levels among all
the cell lines. 7a5 protein expression in prostate cell lines also showed only slight
differences between the cell lines. No substantial differences of either BOG25 or 7a5
were seen between normal and cancerous cell lines or between cancerous cell lines.
Averaged and normalized data for BOG25 expression in breast studies revealed a
14-fold increased expression in one cell line, Hs578T. The other cell lines, including
normal MCF-10 cells, expressed BOG25 at a very low level compared to Hs578T. 7a5
protein expression showed only slight differences in levels among all the breast cell lines.
Subcellular fractionation was performed to determine if the Hs578T cells, which express
very high levels of BOG25, would distribute more BOG25 or 7a5 to either the nucleus or
plasma membrane compared to other breast cell lines. Pro-apoptotic proteins bind and
aggregate with each other, translocate to specific subcellular locations and proteolytically
cleave key proteins to induce cell death. For example, the pro-apoptotic protein Bid is
normally located in the cytosol, and when cleaved by caspase- 8 , it associates with the
mitochondrial membrane to facilitate the release of cytochrome c (Reed, 2000). Upon
release, cytochrome c translocates to the cytoplasm and aggregates with Apaf-1 to form
the apoptosome and activate caspase-9 (Zou et al., 1999). A mutated nuclear export
signal in FADD has shown to reduce apoptosis (Gomez-Angelats and Cidlowski, 2003),
indicating that FADD normally resides in the nucleus and translocates to the plasma
membrane when the extrinsic pathway is engaged. If BOG25 and 7a5 were active in
death receptor apoptosis, one would expect that the BOG25 proteins may translocate
between their subcellular localizations. The NE-PER reagent protocol was used to
determine the subcellular localization of BOG25 and 7a5 proteins. Examination o f the
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results revealed a 1:1 ratio of BOG25 in the PNF and NF in the Hs578T cell line on two
separate sets of cell cultures. 7a5 was found to be higher in the NF than the PNF in all
breast cell lines, however, there was no substantial differential localization to, and
expression in, the Hs578T cell line. Interestingly, the nuclear fractions of 7a5 contained
a doublet band and both bands migrated slightly higher than lOOkD 7a5 in the PNFs.
One possibility is that nuclear 7a5 is phosphorylated as there are 3 tyrosine
phosphorylation sites identified in 7a5.
No substantial differential expression of BOG25 or 7a5 was shown between
fractions and no substantial differential localization was found in either fraction for
Hs578T. Subcellular fractionation studies performed on RPE and COS-7 cells by
Khanobdee et al. (2004 submitted) demonstrated that BOG25 and 7a5 localized to the
nuclear fraction and postnuclear fraction in approximately a 3:1 ratio which is a similar
distribution to that found in breast cells. In addition, BOG25 was determined to localize
to the plasma membrane and nuclear periphery in confocal microscopy studies using
BOG25 fusion proteins expressed from the pEGFP and c-myc tagged pCMV-Tag3
vectors (Khanobdee et al., 2003 Abs and Koppelman et al ., 2003 Abs). Overall, these
studies indicate that neither BOG25 or 7a5 preferentially localize to the nucleus or
cytosolic membranes/plasma membrane in normal compared to cancerous cells, and the
distribution of BOG25 and 7a5 is similar to cell lines not related to breast. If BOG25 or
7a5 localization were important for tumorigenicity, then BOG25 or 7a5 would have
shown a differential localization within the Hs578T cells to avoid apoptosis through
death receptor signaling.
Triplet RT-PCR studies used to determine the regulation level of BOG25 in breast
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cell lines revealed a strong BOG25 band in all three samples of Hs578T. Two samples
showed the BOG25 band in MDA cell lines while no other cell lines expressed the
BOG25 band in all 3 samples. The averaged BOG25 mRNA level for Hs578T was very
high, and the level for MDA was moderate, compared to the cell lines MCF-10, MCF-7
and T-47D. Corresponding triplicate protein samples of breast cell lines reflected the
triplicate mRNA levels where all cell lines showed BOG25 protein expression at a much
lower level than Hs578T. This indicates that there is a possibility of a transcriptional
regulation of BOG25 levels. Triplet RT-PCR studies revealed the correctly sized 7a5
band was detected in all samples, except only once in MDA, where the other two samples
showed a faint band at about 900 bp that could not be subcloned or re-amplified. The
averaged 7a5 mRNA level in the MDA cell line appeared substantially low, but the level
difference is due to the inability to amplify that region of the 7a5 message in 2 of the 3
samples. Averaged 7a5 mRNA levels were lowest in MDA, in contrast to the other cell
lines, which showed comparable levels of 7a5 mRNA. Averaged 7a5 protein data also
showed subtle differences among cell lines and were comparable to mRNA levels except
that protein and message levels did not correlate within the MDA cell line. These results
indicate a steady state level of 7a5 mRNA that correlates to 7a5 protein levels.
The highest BOG25 level in both mRNA and protein was expressed in Hs578T,
which is the rarest form of breast cancer cell line utilized in this study. Hs578T is a
carcinosarcoma, a rare metastatic breast cancer originating in the mammary ducts and the
surrounding connective tissue (Hackett eta l ., 1977; Goodman, 2003; Burdall etal.,
2003). In the bladder cell lines, 7a5 exhibited a very strong correlation between 7a5
protein expression and the increase in stage of bladder transitional cell carcinomas.
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Preliminary studies revealed the highest level of 7a5 was expressed in the most advanced
cancerous bladder cell line used in this study, HTB 5 (stage T 4) (Masters et al., 1986).
HTB 5 cells are derived from an invasive and high-grade metastatic transitional cell
carcinoma. Expression was next highest in the invasive (stage T 3) HTB 1 cell line,
followed by the invasive (stage T2) CRL-1472 cell line and the low-grade and stage
(stage T2) bladder cancer cell line HTB 2 was lowest in expression (Masters et al., 1986).
The high BOG25 protein and mRNA level seen in a rare metastatic breast cancer, and the
strong evidence from preliminary data of 7a5 protein expression following stage
advancement in bladder cancer indicate that BOG25 and 7a5 may be excellent candidates
as breast and bladder cancer prognostic markers, respectively.
Prognosis is the prediction of a probable course or outcome of a disease and in
cancer is influenced by cancer stage, grade and type (Goodman and Kelly Snyder, 2003).
Protein markers are used in determining differential localization of proteins within cells
and changes in expression of specific proteins help to predict recurrence of disease
(Sidransky, 2002). An excellent prognostic marker, Metallothionein 3 (MT-3), has been
shown to be associated with ductal carcinoma in situ in tumors of patients having a poor
outcome (Sens et al., 2001). Also, MT-3 has been analyzed in breast cell lines and was
found to inhibit growth when overexpressed in two cell lines, supporting a possible role
for MT-3 as a prognostic marker in breast cancer (Gurel et al., 2003).
Markers of both the death domain and EH-Network families have been examined
for roles as cancer prognostic markers, although none are as well defined as MT-3. The
death-domain protein Fas, the receptor for Fas-Ligand, has been analyzed as a possible
prognostic marker in breast cancer (Mottolese et a l, 2000). This study found that 75% of
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lymph node-negative breast cancer patients expressed Fas, almost 40% of metastatic
positive patients did not display the receptor, and Fas decreased statistically significantly
as tumor size increased, suggesting that Fas down-regulation could be associated with
poorer clinical outcomes. Another study analyzed Fas in bladder cancer cell lines and
showed that despite a correlation with tumor stage that was highly significant, it was not
related to grade or lymph node status (Maas et a l, 2004). Therefore, the overall
conclusion was that Fas was not a good independent prognostic marker in bladder cancer.
The association of BOG25 in the rare metastatic breast cancer, and 7a5 with transitional
cell carcinoma advancement in stage is exciting, but as seen with Fas in bladder cancer,
further studies are needed to statistically associate BOG25 or 7a5 with particular tumors
or with tumor progression. Methylation of another apoptosis protein containing a Cterminal death domain that is also a tumor suppressor, DAP kinase, has been implicated
in many cancers such as head and neck cancers (Bialik and Kimchi, 2004 In Press).
EH-Network proteins have also been examined as cancer markers. The Epsl5
gene is down-regulated in breast cancer patients with short survival expectancy
(Amatschek et al., 2004). Epsl5 has also been involved in translocations in acute
lymphoblastic and myeloid leukemias and deletions in neuroblastomas (Salcini etal.,
1999). Overexpression of the EGFR substrate Epsl 5 in the presence of EGF, has
transformed NIH 3T3 fibroblast cells and allowed them to grow in soft agar (Fazioli et

al., 1993). The EGFR plays an important role in neoplastic cell proliferation and
metastatic spread (Dancey, 2004) and requires recruitment by coated pits (Di Fiore and
Gill, 1999). The most frequent abnormality in the EGFR in cancers is overexpression
and not mutations within the receptor itself (Dancey, 2004). Another EH-Network
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protein that is a nonneuronal form of API 80, CALM, is involved in leukemia gene
rearrangement (Santolini et al., 1999). Since no single gene or gene product has been
demonstrated to be, by itself, responsible for tumor progression, changes in profiles of
expression of multiple cellular proteins that may be relevant to patient prognosis would
be critical in advancing the field of cancer biology and treatment.
BOG25 and 7a5 comprise a family of hybrid proteins that contain both
endocytosis and apoptosis domains of the EH-Network and death domain families,
respectively. This is the first study to examine the expression of BOG25 and 7a5 in
cancer. In addition, this study is the first to confirm that mRNA for 7a5, the putative
protein identified as similar to BOG25, is being transcribed in breast cell lines. In
summary, this study showed that BOG25 and 7a5 proteins were expressed at a very high
level in the Hs578T breast cell line and the HTB 5 bladder cell line, respectively, in
comparison to normal and other cancerous cells. There is a possible transcription
regulation of BOG25 in breast cell lines as mRNA corresponded to protein. Since the
BOG25 proteins belong to both EH-Network and death domain families, monitoring the
role of their expression during tumor progression may identify BOG25 or 7a5 as
prognostic markers in breast and bladder cancers, respectively.
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